A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates

Summary: Activation of nucleic acid sensing Toll-like receptors (TLRs) in B cells is involved in antiviral responses by promoting B cell activation and germinal center responses. In order to take advantage of this natural pathway for vaccine development, synthetic pathogen-like antigens (PLAs) const...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chang Guo, Yanan Peng, Lin Lin, Xiaoyan Pan, Mengqi Fang, Yun Zhao, Keyan Bao, Runhan Li, Jianbao Han, Jiaorong Chen, Tian-Zhang Song, Xiao-Li Feng, Yahong Zhou, Gan Zhao, Leike Zhang, Yongtang Zheng, Ping Zhu, Haiying Hang, Linqi Zhang, Zhaolin Hua, Hongyu Deng, Baidong Hou
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	COVID-19 SARS-CoV-2 RBD vaccine B cells Toll-like receptor Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6677d99468274bcea69009e391b42d59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6677d99468274bcea69009e391b42d59
record_format	dspace
spelling	oai:doaj.org-article:6677d99468274bcea69009e391b42d592021-11-18T04:52:16ZA pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates2666-379110.1016/j.xcrm.2021.100448https://doaj.org/article/6677d99468274bcea69009e391b42d592021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666379121003165https://doaj.org/toc/2666-3791Summary: Activation of nucleic acid sensing Toll-like receptors (TLRs) in B cells is involved in antiviral responses by promoting B cell activation and germinal center responses. In order to take advantage of this natural pathway for vaccine development, synthetic pathogen-like antigens (PLAs) constructed of multivalent antigens with encapsulated TLR ligands can be used to activate B cell antigen receptors and TLRs in a synergistic manner. Here we report a PLA-based coronavirus disease 2019 (COVID-19) vaccine candidate designed by combining a phage-derived virus-like particle carrying bacterial RNA as TLR ligands with the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein as the target antigen. This PLA-based vaccine candidate induces robust neutralizing antibodies in both mice and non-human primates (NHPs). Using a NHP infection model, we demonstrate that the viral clearance is accelerated in vaccinated animals. In addition, the PLA-based vaccine induces a T helper 1 (Th1)-oriented response and a durable memory, supporting its potential for further clinical development.Chang GuoYanan PengLin LinXiaoyan PanMengqi FangYun ZhaoKeyan BaoRunhan LiJianbao HanJiaorong ChenTian-Zhang SongXiao-Li FengYahong ZhouGan ZhaoLeike ZhangYongtang ZhengPing ZhuHaiying HangLinqi ZhangZhaolin HuaHongyu DengBaidong HouElsevierarticleCOVID-19SARS-CoV-2RBDvaccineB cellsToll-like receptorMedicine (General)R5-920ENCell Reports Medicine, Vol 2, Iss 11, Pp 100448- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 RBD vaccine B cells Toll-like receptor Medicine (General) R5-920
spellingShingle	COVID-19 SARS-CoV-2 RBD vaccine B cells Toll-like receptor Medicine (General) R5-920 Chang Guo Yanan Peng Lin Lin Xiaoyan Pan Mengqi Fang Yun Zhao Keyan Bao Runhan Li Jianbao Han Jiaorong Chen Tian-Zhang Song Xiao-Li Feng Yahong Zhou Gan Zhao Leike Zhang Yongtang Zheng Ping Zhu Haiying Hang Linqi Zhang Zhaolin Hua Hongyu Deng Baidong Hou A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
description	Summary: Activation of nucleic acid sensing Toll-like receptors (TLRs) in B cells is involved in antiviral responses by promoting B cell activation and germinal center responses. In order to take advantage of this natural pathway for vaccine development, synthetic pathogen-like antigens (PLAs) constructed of multivalent antigens with encapsulated TLR ligands can be used to activate B cell antigen receptors and TLRs in a synergistic manner. Here we report a PLA-based coronavirus disease 2019 (COVID-19) vaccine candidate designed by combining a phage-derived virus-like particle carrying bacterial RNA as TLR ligands with the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein as the target antigen. This PLA-based vaccine candidate induces robust neutralizing antibodies in both mice and non-human primates (NHPs). Using a NHP infection model, we demonstrate that the viral clearance is accelerated in vaccinated animals. In addition, the PLA-based vaccine induces a T helper 1 (Th1)-oriented response and a durable memory, supporting its potential for further clinical development.
format	article
author	Chang Guo Yanan Peng Lin Lin Xiaoyan Pan Mengqi Fang Yun Zhao Keyan Bao Runhan Li Jianbao Han Jiaorong Chen Tian-Zhang Song Xiao-Li Feng Yahong Zhou Gan Zhao Leike Zhang Yongtang Zheng Ping Zhu Haiying Hang Linqi Zhang Zhaolin Hua Hongyu Deng Baidong Hou
author_facet	Chang Guo Yanan Peng Lin Lin Xiaoyan Pan Mengqi Fang Yun Zhao Keyan Bao Runhan Li Jianbao Han Jiaorong Chen Tian-Zhang Song Xiao-Li Feng Yahong Zhou Gan Zhao Leike Zhang Yongtang Zheng Ping Zhu Haiying Hang Linqi Zhang Zhaolin Hua Hongyu Deng Baidong Hou
author_sort	Chang Guo
title	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
title_short	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
title_full	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
title_fullStr	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
title_full_unstemmed	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
title_sort	pathogen-like antigen-based vaccine confers immune protection against sars-cov-2 in non-human primates
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6677d99468274bcea69009e391b42d59
work_keys_str_mv	AT changguo apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yananpeng apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT linlin apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT xiaoyanpan apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT mengqifang apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yunzhao apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT keyanbao apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT runhanli apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT jianbaohan apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT jiaorongchen apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT tianzhangsong apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT xiaolifeng apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yahongzhou apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT ganzhao apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT leikezhang apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yongtangzheng apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT pingzhu apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT haiyinghang apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT linqizhang apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT zhaolinhua apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT hongyudeng apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT baidonghou apathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT changguo pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yananpeng pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT linlin pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT xiaoyanpan pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT mengqifang pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yunzhao pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT keyanbao pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT runhanli pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT jianbaohan pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT jiaorongchen pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT tianzhangsong pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT xiaolifeng pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yahongzhou pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT ganzhao pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT leikezhang pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT yongtangzheng pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT pingzhu pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT haiyinghang pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT linqizhang pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT zhaolinhua pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT hongyudeng pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates AT baidonghou pathogenlikeantigenbasedvaccineconfersimmuneprotectionagainstsarscov2innonhumanprimates
_version_	1718424979079430144

A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates

Ejemplares similares